Is ADC a rising star in solid tumor? An umbrella review of systematic reviews and meta-analyses
Abstract Background Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the potency of highly cytotoxic drugs and are known as panaceas, completely changing the treatment paradigm for solid tumors. Compared with other anti-cancer drugs, do they have better efficacy...
I tiakina i:
| Ngā kaituhi matua: | , , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
BMC
2025-02-01
|
| Rangatū: | BMC Cancer |
| Ngā marau: | |
| Urunga tuihono: | https://doi.org/10.1186/s12885-025-13726-8 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|